Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancerDavid Miles, Giulia Bianchi, Diego Kaen et al.|Annals of Oncology|2021Cited by 724
PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in ItalyFrancesco Cognetti, Sandro Barni, Riccardo Masetti et al.|npj Breast Cancer|2021Cited by 29
Abstract P5-01-07: Bioitalee - Biomarker analysis on liquid biopsies of patients treated with ribociclib and letrozole as first-line therapy for advanced breast cancer (aBC) (NCT03439046)Michelino De Laurentiis, Grazia Arpino, Luca Malorni et al.|Cancer Research|2020Cited by 6
97P Genomic bases of endocrine sensitivity in triple-positive early breast cancer: A translational analysis of the PerELISA trialGaia Griguolo, V. Guarneri, Giancarlo Bisagni et al.|Annals of Oncology|2022Cited by 0